Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2018

  1. 12/12/2018
    MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis
  2. 07/12/2018
    Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
    No download available
  3. 02/12/2018
    MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018
  4. 26/11/2018
    MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis
  5. 19/11/2018
    MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa
  6. 15/11/2018
    MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210
  7. 05/11/2018
    MorphoSys AG Announces Third Quarter 2018 Results
  8. 01/11/2018
    MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting
  9. 29/10/2018
    MorphoSys to Host Q3 2018 Conference Call on November 6, 2018
  10. 21/10/2018
    MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2018

  1. 07/12/2018
    Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
    No download available
  2. 19/07/2018
    Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018
    No download available
  3. 18/04/2018
    Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
  4. 09/04/2018
    Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States
  5. 22/03/2018
    Ad hoc: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering

2017

  1. 30/11/2017
    Ad hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
    No download available
  2. 23/10/2017
    Ad hoc: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
    No download available
  3. 21/07/2017
    Ad hoc: MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma
    No download available
  4. 13/07/2017
    Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
    No download available

2016

  1. 15/11/2016
    Ad hoc: MorphoSys Raises EUR 115 million in Private Placement

Pages

Presentations
and conferences

Thursday, December 6, 2018
Presentation: Berenberg European Conference 2018

Jens Holstein presented the Company at the Berenberg European Conference in Pennyhill, UK on Thursday, December 6, 2018.

DocumentFile info
Company Update 4.51 MB

Archive

Date
Title
MP3

2018

  1. 12/06/2018

    Presentation: Berenberg European Conference 2018

  2. 12/05/2018

    Webcast: Investor & Analyst Event

  3. 11/28/2018

    Presentation: Piper Jaffray Annual Healthcare Conference

  4. 11/26/2018

    Presentation: German Eigenkapitalforum

  5. 11/22/2018

    Presentation: Bryan Garnier 6th Annual Healthcare Conference

  6. 11/06/2018

    Conference Call and Webcast: Q3 2018 Financial Results

  7. 10/03/2018

    Webcast: Leerink Partners Roundtable Series: Rare Disease & Oncology

  8. 09/25/2018

    Presentation: Berenberg and Goldman Sachs Seventh German Corporate Conference

  9. 09/24/2018

    Presentation: Baader Investment Conference

  10. 09/07/2018

    Presentation: Goldman Sachs Eighth Annual Biotech Symposium

  11. 08/28/2018

    Presentation: Commerzbank Sector Conference

  12. 08/02/2018

    Conference Call and Webcast: Q2 2018 Financial Results

  13. 06/20/2018

    Webcast: JMP Securities Life Sciences Conference

  14. 06/06/2018

    Presentation: dbAccess Berlin

  15. 05/21/2018

    Presentation: UBS Global Healthcare Conference

  16. 05/03/2018

    Conference Call and Webcast: Q1 2018 Financial Results

  17. 03/13/2018

    Year End 2017 Conference Call and Webcast

  18. 02/21/2018

    Presentation: Oddo Seydler German Conference

  19. 02/15/2018

    Webcast: LEERINK Partners 7th Annual Global Healthcare Conference

  20. 01/15/2018

    Presentation: Kepler Cheuvreux German Corporate Conference

  21. 01/10/2018

    Webcast: 36th Annual J.P. Morgan Healthcare Conference

Pages

Pictures

Management Board

Dr. Simon E. Moroney

Chief Executive Officer,
MorphoSys AG

Jens Holstein

Chief Financial Officer,
MorphoSys AG

Dr. Malte Peters

Chief Development Officer,
MorphoSys AG

Dr. Markus Enzelberger

Chief Scientific Officer,
MorphoSys AG

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".